{"pmid":32466136,"title":"Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.","text":["Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.","The COVID-19 global pandemic is accelerating investigations for effective vaccines and repurposable validated therapeutics [...].","Int J Environ Res Public Health","Bischof, Evelyne","Oertelt-Prigione, Sabine","Morgan, Rosemary","Klein, Sabra L","The Sex And Gender In Covid Clinical Trials Working Group Sgc","Gender And Covid Working Group","32466136"],"abstract":["The COVID-19 global pandemic is accelerating investigations for effective vaccines and repurposable validated therapeutics [...]."],"journal":"Int J Environ Res Public Health","authors":["Bischof, Evelyne","Oertelt-Prigione, Sabine","Morgan, Rosemary","Klein, Sabra L","The Sex And Gender In Covid Clinical Trials Working Group Sgc","Gender And Covid Working Group"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32466136","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijerph17103715","weight":0,"_version_":1668420887206952960,"score":9.490897,"similar":[{"pmid":32487260,"pmcid":"PMC7266425","title":"Precision medicine for COVID-19: a call for better clinical trials.","text":["Precision medicine for COVID-19: a call for better clinical trials.","Crit Care","Shrestha, Gentle Sunder","Paneru, Hem Raj","Vincent, Jean-Louis","32487260"],"journal":"Crit Care","authors":["Shrestha, Gentle Sunder","Paneru, Hem Raj","Vincent, Jean-Louis"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32487260","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1186/s13054-020-03002-5","topics":["Treatment"],"weight":1,"_version_":1668892169444786176,"score":70.64675},{"pmid":32441462,"title":"Time to step up: A call to action for the clinical and quantitative pharmacology community to accelerate therapeutics for COVID-19.","text":["Time to step up: A call to action for the clinical and quantitative pharmacology community to accelerate therapeutics for COVID-19.","The global response to finding therapeutics for COVID-19 is chaotic even if well intentioned. There is an opportunity, but more importantly, an obligation for the global clinical and quantitative pharmacology community to come together and use our state-of-the-art tools and expertise to help society accelerate therapeutics to fight COVID-19. This brief commentary is a call to action and highlights how the global pharmacology community should contribute to the COVID-19 pandemic and prepare for future pandemics.","Clin Transl Sci","Hartman, Dan","Kern, Steven","Brown, Fran","Minton, Suzanne K","Rayner, Craig R","32441462"],"abstract":["The global response to finding therapeutics for COVID-19 is chaotic even if well intentioned. There is an opportunity, but more importantly, an obligation for the global clinical and quantitative pharmacology community to come together and use our state-of-the-art tools and expertise to help society accelerate therapeutics to fight COVID-19. This brief commentary is a call to action and highlights how the global pharmacology community should contribute to the COVID-19 pandemic and prepare for future pandemics."],"journal":"Clin Transl Sci","authors":["Hartman, Dan","Kern, Steven","Brown, Fran","Minton, Suzanne K","Rayner, Craig R"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441462","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/cts.12824","keywords":["covid-19","antiviral","chloroquine","clinical pharmacology","coronavirus","drug development","hydroxychloroquine","ivermectin","lopinavir","pandemic","ritonavir"],"weight":0,"_version_":1667535119464792064,"score":65.72406},{"pmid":32334651,"pmcid":"PMC7180034","title":"Global call to action for inclusion of migrants and refugees in the COVID-19 response.","text":["Global call to action for inclusion of migrants and refugees in the COVID-19 response.","Lancet","Orcutt, Miriam","Patel, Parth","Burns, Rachel","Hiam, Lucinda","Aldridge, Rob","Devakumar, Delan","Kumar, Bernadette","Spiegel, Paul","Abubakar, Ibrahim","32334651"],"journal":"Lancet","authors":["Orcutt, Miriam","Patel, Parth","Burns, Rachel","Hiam, Lucinda","Aldridge, Rob","Devakumar, Delan","Kumar, Bernadette","Spiegel, Paul","Abubakar, Ibrahim"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32334651","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/S0140-6736(20)30971-5","link_erratum_in":"32353325","topics":["Prevention"],"weight":1,"_version_":1666138494068588544,"score":63.124542},{"pmid":32350686,"pmcid":"PMC7189176","title":"Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.","text":["Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.","The World Health Organization (WHO) called the outbreak of coronavirus infectious disease-2019 (COVID-19) a \"Public Health Emergency of International Concern\" (PHEIC). According to the WHO, Centers for Disease Control and Prevention (CDC), and the US Food and Drug Administration (FDA), currently there are no medicines or vaccines that have been claimed to be useful in the prevention or treatment of COVID-19. Several existing antiviral drugs, previously developed or used as treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), human immunodeficiency virus (HIV), and malaria, are being investigated as COVID-19 treatments and some of them are being used in clinical trials. According to the CDC and Chinese treatment guidelines for COVID-19, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and one of the investigational agents (remdesivir) are recommended in critically ill older patients. The use of other potential drugs reported in different studies may be considered if treatment with first-line drugs is ineffective. There are currently no complete data available from large randomized clinical trials (RCTs) to provide clinical guidance on the use, dosing, or duration to validate the effective role, safety profile, and adverse effects of all of the trial drugs for prophylaxis or treatment of COVID-19. Until now, it is still unclear which drug can successfully fight against the disease. Therefore, for the better safety of patients with COVID-19, further clinical trials and large randomized controlled studies are needed to validate the effective role, safety profile, and adverse effects of all the potential drugs. Such a measure requires action at the global level.","Adv Ther","Khan, Zakir","Karatas, Yusuf","Rahman, Hazir","32350686"],"abstract":["The World Health Organization (WHO) called the outbreak of coronavirus infectious disease-2019 (COVID-19) a \"Public Health Emergency of International Concern\" (PHEIC). According to the WHO, Centers for Disease Control and Prevention (CDC), and the US Food and Drug Administration (FDA), currently there are no medicines or vaccines that have been claimed to be useful in the prevention or treatment of COVID-19. Several existing antiviral drugs, previously developed or used as treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), human immunodeficiency virus (HIV), and malaria, are being investigated as COVID-19 treatments and some of them are being used in clinical trials. According to the CDC and Chinese treatment guidelines for COVID-19, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and one of the investigational agents (remdesivir) are recommended in critically ill older patients. The use of other potential drugs reported in different studies may be considered if treatment with first-line drugs is ineffective. There are currently no complete data available from large randomized clinical trials (RCTs) to provide clinical guidance on the use, dosing, or duration to validate the effective role, safety profile, and adverse effects of all of the trial drugs for prophylaxis or treatment of COVID-19. Until now, it is still unclear which drug can successfully fight against the disease. Therefore, for the better safety of patients with COVID-19, further clinical trials and large randomized controlled studies are needed to validate the effective role, safety profile, and adverse effects of all the potential drugs. Such a measure requires action at the global level."],"journal":"Adv Ther","authors":["Khan, Zakir","Karatas, Yusuf","Rahman, Hazir"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350686","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1007/s12325-020-01351-9","keywords":["adverse effects","china","chloroquine","coronavirus infectious disease-2019 (covid-19)","drugs","mers","sars","therapy"],"locations":["Concern","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine","remdesivir","Chloroquine","lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1666138495662424064,"score":60.620235},{"pmid":32320331,"title":"Sex and Gender Disparities in the COVID-19 Pandemic.","text":["Sex and Gender Disparities in the COVID-19 Pandemic.","J Womens Health (Larchmt)","Gausman, Jewel","Langer, Ana","32320331"],"journal":"J Womens Health (Larchmt)","authors":["Gausman, Jewel","Langer, Ana"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320331","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1089/jwh.2020.8472","link_comment_for":"32171067","topics":["Prevention"],"weight":1,"_version_":1666138493633429504,"score":60.057602}]}